ALEXANDRIA, Va., July 9 -- United States Patent no. 12,351,614, issued on July 8, was assigned to Orionis Biosciences Inc. (Waltham, Mass.) and Orionis Biosciences BV (Zwijnaarde, Belgium).
"CLEC9A-based chimeric protein complexes" was invented by Nikolai Kley (Waltham, Mass.), Erik Depla (Zwijnaarde, Belgium), Lennart Zabeau (Zwijnaarde, Belgium) and Jan Tavernier (Zwijnaarde, Belgium).
According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates, in part, to chimeric protein complexes including an anti-Clec9A targeting moiety, a modified Fc domain, and a modified human IFNAlpha and their use as therapeutic agents. The present invention further relates to pharmaceutical compositions comprising...